ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,062.00
-0.10%
다우존스 지수
40,003.59
0.34%
Bitcoin
67,254.34
0.47%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. AMEX
  6. Actinium Pharmaceuticals Inc (ATNM)

  7. Actinium Pharmaceuticals Inc (ATNM) 뉴스

ATNM

Actinium Pharmaceuticals (ATNM)

Actinium Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:AMEX:ATNM
일자시간출처헤드라인심볼기업
2024/05/1521:30PR Newswire (US)Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market OpportunityAMEX:ATNMActinium Pharmaceuticals Inc
2024/05/1507:38PR Newswire (US)Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the PhasAMEX:ATNMActinium Pharmaceuticals Inc
2024/05/1321:30PR Newswire (US)Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
2024/05/0721:00PR Newswire (US)Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas SouthwesternAMEX:ATNMActinium Pharmaceuticals Inc
2024/04/1821:00PR Newswire (US)Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
2024/04/0121:00PR Newswire (US)Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant AnnualAMEX:ATNMActinium Pharmaceuticals Inc
2024/03/2620:18PR Newswire (US)Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell TherapyAMEX:ATNMActinium Pharmaceuticals Inc
2024/03/1120:30PR Newswire (US)Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market DemandAMEX:ATNMActinium Pharmaceuticals Inc
2024/02/2621:30PR Newswire (US)Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTAMEX:ATNMActinium Pharmaceuticals Inc
2024/02/2321:30PR Newswire (US)Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBAMEX:ATNMActinium Pharmaceuticals Inc
2024/02/1006:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
2024/02/0614:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:ATNMActinium Pharmaceuticals Inc
2024/02/0307:03Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
2024/01/0221:30PR Newswire (US)Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®AMEX:ATNMActinium Pharmaceuticals Inc
2023/12/3007:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/3007:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/3007:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/3007:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/3007:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/1122:15PR Newswire (US)Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 MutationAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/1121:45PR Newswire (US)Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid LeukemiaAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/0822:00PR Newswire (US)Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & ExpositionAMEX:ATNMActinium Pharmaceuticals Inc
2023/12/0207:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:ATNMActinium Pharmaceuticals Inc
2023/11/1007:09Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersAMEX:ATNMActinium Pharmaceuticals Inc
2023/11/1007:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:ATNMActinium Pharmaceuticals Inc
2023/11/0621:30PR Newswire (US)Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy CombinationsAMEX:ATNMActinium Pharmaceuticals Inc
2023/11/0305:15PR Newswire (US)Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023AMEX:ATNMActinium Pharmaceuticals Inc
2023/11/0222:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:ATNMActinium Pharmaceuticals Inc
2023/11/0222:05PR Newswire (US)Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA TrialAMEX:ATNMActinium Pharmaceuticals Inc
2023/10/0420:30PR Newswire (US)Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell TherapyAMEX:ATNMActinium Pharmaceuticals Inc
 검색 관련기사 보기:AMEX:ATNM

최근 히스토리

LATK
WDRUSDT
Wider
BIT
UI346X
UniCredit
LSE
SAT
Sat Sol
LSE
SWJ
John Swan
LSE
IEUT
Ishr Eurof 100
BIT
F35349
Vontobel Financial Produ...
EU
3889T
3889T
BIT
F17289
Vontobel Financial Produ...
COIN
P2TEUR
P2 Token
LSE
0F1C
Keskisuomalainen Oyj
EU
NEXTA
Nextensa
COIN
ACRVETH
Aladdin cvxCRV
BIT
F11208
Vontobel Financial Produ...
COIN
APTBRL
Aptos
LBNK
MORIEUSDT
Morie INU
COIN
MYOBUUSD
Myobu
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유